| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:22446829 | IVTH | 0.01 - 10 mg/L | 0.1 - 10 mg/L | Increased estradiol levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.01 - 10 mg/L | 0.1 - 10 mg/L | Increased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.01 - 10 mg/L | 10 mg/L | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| PMID:26183808 | IVR | 300 mg/kg | 300 mg/kg | Decreased testis weights | Reproductive endocrine-mediated perturbations |
| IVR | 300 mg/kg | 300 mg/kg | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 300 mg/kg | 300 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 100 mg/kg | 100 mg/kg | Affects the biochemical composition of liver | Hepatic endocrine-mediated perturbations | |
| PMID:35780845 | IVR | 2 - 6 mg/kg | 2 - 6 mg/kg | Increased LDL levels | Metabolic endocrine-mediated perturbations |
| IVR | 6 mg/kg | 6 mg/kg | Increased Non esterified Fatty acid (NEFA) levels | Metabolic endocrine-mediated perturbations | |
| IVR | 6 mg/kg | 6 mg/kg | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVR | 6 mg/kg | 6 mg/kg | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 2 - 6 mg/kg | 2 - 6 mg/kg | Induce behavioral changes | Neurological endocrine-mediated perturbations | |
| IVR | 6 mg/kg | 6 mg/kg | Increased adiposity | Metabolic endocrine-mediated perturbations | |
| IVR | 2 - 6 mg/kg | 2 - 6 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 6 mg/kg | 6 mg/kg | Increased body weights | Metabolic endocrine-mediated perturbations | |
| IVR | mg/kg | - | Changes in morphology of adipose tissue | Metabolic endocrine-mediated perturbations | |
| PMID:8314462 | IVR | 44 mg/kg | 44 mg/kg | Hematopietic carcinoma | Endocrine-mediated cancer;Immunological endocrine-mediated perturbations |
| IVR | 88 mg/kg | 88 mg/kg | Changes in brain morphology | Neurological endocrine-mediated perturbations | |
| IVR | 88 mg/kg | 88 mg/kg | Hematopietic carcinoma | Endocrine-mediated cancer;Immunological endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.